Navigation Links


INO in Biological Technology

Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target

...nd has issued a $3.57 price target on Inovio Biomedical Corporation (Amex: ino ). "The proposed merger of Inovio and VGX would create a comprehensive DNA ...ap.com . About Inovio Biomedical Corporation: Inovio Biomedical (Amex: ino ) is focused on developing multiple DNA-based immunotherapies. Inovio is a ...

Atom Medical Adopts Masimo Rainbow SET Technology

...emia. According to the American Academy of Pediatrics, "infants who receive ino therapy should be monitored according to institutionally derived protocols designed to avoid the potential toxic effects associated with ino administration. These effects include methemoglobinemia (secondary to exces...

Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target

...nd has issued a $3.52 price target on Inovio Biomedical Corporation (Amex: ino ). "Inovio has compelling pre-clinical and clinical data regarding the abil...tap.com . About Inovio Biomedical Corporation: Inovio Biomedical (AMEX: ino ) is focused on developing multiple DNA-based immunotherapies. Inovio is a ...

Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.

...has nearly 35 years of broad and global experience in the pharmaceutical industry and most recently served as President and Chief Executive Officer of ino Therapeutics LLC., a specialty pharmaceutical company with strengths in development, marketing, and sales of critical care drugs and drug/device combi...

Basic Scientist Mark Roth Wins MacArthur Fellowship

...s work forward into the clinical setting, Roth in 2005 founded a Seattle biotechnology company called Ikaria Inc., which earlier this year merged with ino Therapeutics to become Ikaria Holdings, a leader in the development of therapeutic gases for use in critical-care medicine. The company, based in Clin...

Hiring in the name of talent

...Case as your risk manager, Luke Over as your report editor, and Minnie Mumwage as your compensation analyst. But you may want to take a pass on Howard ino as your research manager and Lou Pole as your tax adviser. Know someone with an interesting job-related name? We'd love to hear it! E-mail Tony a...
Other Tagscoupledcoupledslaughteradoptadopt
(Date:12/16/2009)... LONDON, Dec. 16 European Union ... protecting their borders, which are increasingly subjected ... High investment in advanced technology security and ... market. ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, ... http://www.aerospace.frost.com ), Border Security Market Assessment ...
(Date:12/15/2009)... COLUMBIA, Mo. As soon as babies are ... as jaundice and e-coli. For up to a month, ... Although these infections are often minor, they can lead ... newborns, immune systems, University of Missouri researchers have pinpointed ... lead to an immune-strengthening vaccine. , "We,re trying to ...
(Date:12/15/2009)... agreement with the British Society for Research on Ageing ... Biogerontology for an initial period of three ... the Biogerontology editorial board and will acquire ... sponsor the society and provide society members with free ... . , Biogerontology offers a platform for ...
Breaking Biology News(10 mins):Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3Researchers work on vaccine to improve immune system in newborns 2Sizable Health Disparities Evident in Every State Between Women of Different Racial and Ethnic Groups 48394 1Sizable Health Disparities Evident in Every State Between Women of Different Racial and Ethnic Groups 48394 2Sizable Health Disparities Evident in Every State Between Women of Different Racial and Ethnic Groups 48394 3University of Texas Picosatellite to be launched from space shuttle to begin milestone mission 12548 1University of Texas Picosatellite to be launched from space shuttle to begin milestone mission 12548 2University of Texas Picosatellite to be launched from space shuttle to begin milestone mission 12548 3Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 1Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 2Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 3Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 4Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 5Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 6Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 7Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 8Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 9Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 10Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 11Two Year Data Show Patients Receiving SIMPONI 28TM 29 28golimumab 29 Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis a 4578 12
(Date:12/16/2009)... half, but use in humans is still far off , , ... nature, researchers have built and tested synthetic versions of the ... other cases where blood just won,t stop flowing. , "We ... in degradable stitches, which dissolve in the body," said Erin ... Reserve University, and lead author of a report published ...
(Date:12/16/2009)... for use, expert says, , , WEDNESDAY, Dec. 16 (HealthDay ... less likely to die when they receive an implantable ... included 4,685 people, ages 65 to 85, who were ... fraction (a measure of the heart,s pumping ability) of ... those who were treated with standard medication and an ...
(Date:12/16/2009)... -- Medical travel facilitator Companion Global Healthcare Inc. ... into its network of international hospitals that treat ... at mainland U.S. facilities. ,, The announcement means ... and preferred pricing for its individual clients and ... HIMA San Pablo Bayamon or HIMA San Pablo ...
(Date:12/16/2009)... -- Quantros, Inc., a leading provider of safety ... the healthcare industry, announces the creation of a ... software industry veteran Michael Tulloch, MBA, as Director ... the company,s new Marlborough, MA office. ,, "The ... explains Tulloch. "Quantros has been developing software for ...
(Date:12/16/2009)... families of sick and dying hospitalized children ask their ... do pediatricians respond to such personal requests? While increasing ... some patients and families cope with serious illness, a ... families and patients who raise the issue of prayer, ... of Southern Medical Journal , Brandeis and Rice ...
Breaking Medicine News(10 mins):Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:Implanted Defibrillator Might Extend Life 2Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2Health News:Safety and Quality Software Developer Quantros, Inc. Launches Healthcare IT Consulting Division 2Health News:Prayer on the hospital floor 2
Other Contentspseudogoutelasticumpseudoxanthomapsittacosispsoriasispsoriasispsoriasispsoriasispsychiatrypsychiatrypsychiatrypsychiatry